Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.60, FiscalAI reports.
Cadrenal Therapeutics Price Performance
Shares of NASDAQ:CVKD traded up $0.01 during trading on Tuesday, hitting $1.42. The company had a trading volume of 17,552 shares, compared to its average volume of 183,494. The stock has a market cap of $5.05 million, a price-to-earnings ratio of -0.29 and a beta of 1.94. Cadrenal Therapeutics has a one year low of $0.82 and a one year high of $12.50. The company has a fifty day simple moving average of $1.09 and a two-hundred day simple moving average of $3.61.
Wall Street Analyst Weigh In
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Thursday, October 15th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Cadrenal Therapeutics presently has an average rating of “Hold” and a consensus target price of $13.00.
View Our Latest Analysis on Cadrenal Therapeutics
About Cadrenal Therapeutics
Cadrenal Therapeutics is a clinical-stage biopharmaceutical company developing treatments to prevent blood clots in people with cardiovascular conditions that require long-term anticoagulation. Its pipeline centers on tecarfarin, an investigational oral anticoagulant being developed as a potential alternative to warfarin. Tecarfarin is designed to be processed through a different metabolic pathway than warfarin and is being studied for patients with needs such as mechanical heart valves and end-stage renal disease.
Read More
- Five stocks we like better than Cadrenal Therapeutics
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
